These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36430675)

  • 21. Cell-Free DNA Fragmentomics: The Novel Promising Biomarker.
    Qi T; Pan M; Shi H; Wang L; Bai Y; Ge Q
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
    Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
    Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
    Tan G; Chu C; Gui X; Li J; Chen Q
    Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep cfDNA fragment end profiling enables cancer detection.
    Zhitnyuk YV; Koval AP; Alferov AA; Shtykova YA; Mamedov IZ; Kushlinskii NE; Chudakov DM; Shcherbo DS
    Mol Cancer; 2022 Jan; 21(1):26. PubMed ID: 35062943
    [No Abstract]   [Full Text] [Related]  

  • 27. Cell-Free DNA: Applications in Different Diseases.
    Ranucci R
    Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When Tissue Is the Issue: Expanding Cell-Free DNA "Liquid Biopsies" to Supernatants and Nonplasma Biofluids.
    Paulson V; Konnick EQ; Lockwood CH
    Clin Lab Med; 2022 Sep; 42(3):485-496. PubMed ID: 36150825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation and breast cancer: A way forward (Review).
    Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating Cell Free Nuclear DNA, Mitochondrial DNA and Global DNA Methylation: Potential Noninvasive Biomarkers for Breast Cancer Diagnosis.
    Pasha HA; Rezk NA; Riad MA
    Cancer Invest; 2019; 37(9):432-439. PubMed ID: 31516038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
    Seyhan AA
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
    Ponti G; Manfredini M; Tomasi A
    Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs.
    Meng Y; Bian L; Zhang M; Bo F; Lu X; Li D
    Biomark Med; 2020 Oct; 14(14):1393-1404. PubMed ID: 33073579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies.
    Jiang P; Chan KCA; Lo YMD
    J Hepatol; 2019 Aug; 71(2):409-421. PubMed ID: 31004682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy in colorectal cancer: Onward and upward.
    Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
    Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy in CNS tumors: Current status & future perspectives.
    Husain N; Husain A; Mishra S; Srivastava P
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bridging biological cfDNA features and machine learning approaches.
    Moser T; Kühberger S; Lazzeri I; Vlachos G; Heitzer E
    Trends Genet; 2023 Apr; 39(4):285-307. PubMed ID: 36792446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
    Kerachian MA; Poudineh A; Thiery JP
    Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.
    Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J
    J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.